EPO Risks May Now Outweigh Benefits In Cancer Patients, FDA Documents Say

FDA briefing documents for May 10 Oncologic Drugs Advisory Committee meeting say evidence about the risks of mortality and tumors from use of erythropoiesis-stimulating agents has grown, while the products’ main benefit – reducing blood transfusions – is no longer as important as it once was.